Showing 4601-4610 of 10520 results for "".
- Verrica Pharmaceuticals Update: Company Announces First Sale of YCANTH to FFF Enterpriseshttps://practicaldermatology.com/news/verrica-pharmaceuticals-update-company-announces-first-sale-of-ycanth-to-fff-enterprises/2461957/Verrica Pharmaceuticals Inc. announced the first commercial sale of YCANTH to its exclusive distributor, FFF Enterprises Inc. (FFF). “As one of the nation’s most trusted specialty pharmaceutical distributors, FFF is well positioned to help Verrica introduce YCANTH&trad
- DermWire’s Practical Guide to Assessing Quality of Life and Mood in Patients With Chronic Skin Diseaseshttps://practicaldermatology.com/news/dermwires-practical-guide-to-assessing-quality-of-life-and-mood-in-patients-with-chronic-skin-diseases/2461936/Psoriasis, atopic dermatitis (AD), hidradenitis suppurativa (HS), and other dermatological conditions often go more than skin deep and can have profound effects on a patient's quality of life, mood, and mental health. This is the main takeaway from a panel discussion on the psy
- Revealed: Why Tans Appear After Leaving the Beachhttps://practicaldermatology.com/news/revealed-why-tans-appear-after-leaving-the-beach/2461906/New research uncovers the science behind why the body's tanning process does not occur immediately after sun exposure, but only after a few hours or even days. The mechanism that repairs our DNA takes precedence over all other systems in the cell, temporarily inhibiting the pi
- Curology Survey: Back-to-School Skin Woes Plague Studentshttps://practicaldermatology.com/news/curology-survey-back-to-school-skin-woes-plague-students/2461903/When thinking of going back to school, nearly 72% of students report feeling the pressure to look "perfect" by higher beauty standards set by social media, according to a survey of 2,000 American teens and young adults sponsored by Curology. What’s more, 25% of students
- ASA’s SPOTS Program Wins an International Award for Social Responsibility in Dermatologyhttps://practicaldermatology.com/news/asas-spots-program-wins-an-international-award-for-social-responsibility-in-dermatology/2461880/The American Skin Association (ASA)’s SPOTS (Sun Protection Outreach Teaching by Students) program was selected as one of five "Top Projects" in North America by the International Awards for Social Responsibility in Dermatology. The awards are a partnersh
- Almirall on Track for Net-Zero GHG emissions by 2050https://practicaldermatology.com/news/almirall-on-track-for-net-zero-ghg-emissions-by-2050/2461877/The Science-Based Targets initiative (SBTi) has validated Almirall’s Environmental, Social and Governance (ESG) targets to achieve net zero greenhouse gas (GHG) emissions across the value chain by 2050, under the 'Net-Zero Standard'. The company has als
- Azitra Adds Barbara Ryan and John Schroer to Board of Directorshttps://practicaldermatology.com/news/azitra-adds-barbara-ryan-and-john-schroer-to-board-of-directors/2461876/Barbara Ryan and John Schroer joined Azitra, Inc.’s board of directors. "We are thrilled to further strengthen the Azitra team by welcoming Barbara and John to our board and by leveraging their wealth of knowledge in biotech, corporate strategy, and capital markets,
- News You Can Use: GW, Pfizer Offering Grants to Improve Access to Teledermatology in Underserved Areashttps://practicaldermatology.com/news/news-you-can-use-gw-pfizer-offering-grants-to-improve-access-to-teledermatology-in-underserved-areas/2461865/The George Washington University (GW) School of Medicine and Health Sciences (SMHS) and Pfizer Global Medical Grants are collaborating to offer a grant opportunity focused on broad implementation of GW’s Teledermatology Help Desk Clinic model in underserved areas across the United States.</
- Laura Bush Named SDPA’s Board Presidenthttps://practicaldermatology.com/news/laura-bush-named-sdpas-board-president/2461847/Georgia-based dermatology physician assistant Laura Bush is the new president of the Society of Dermatology Physician Assistant's (SDPA) Board of Directors. Bush, a DermPA with Fayette Area Dermatology in Fayetteville, Georgia, will serve a one-year term leading the nine-membe
- WCD News: Janssen's Oral IL-23 Blocker Shows Promise in Phase 2b PsO Studyhttps://practicaldermatology.com/news/wcd-news/2461839/Janssen’s novel oral interleukin-23 receptor (IL-23R) antagonist peptide JNJ-2113 performed well in the Phase 2b FRONTIER 1 clinical trial of adults with moderate-to-severe plaque psoriasis (PsO), the Company reports. JNJ-2113 is a novel oral IL-23R antagonist peptide that binds w